Literature DB >> 33574117

FGFR Inhibitor Stymies Gastric Cancer.

.   

Abstract

In the phase II FIGHT trial, adding bemarituzumab to chemotherapy led to longer progression-free survival and overall survival in patients with advanced FGFR2b-positive gastric or gastroesophageal junction cancers. However, the agent was also associated with more side effects, including eye problems. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID： 33574117     DOI： 10.1158/2159-8290.CD-NB2021-0312

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

1.  TIM3+ cells in gastric cancer: clinical correlates and association with immune context.

Authors:  Ke Chen; Yun Gu; Yifan Cao; Hanji Fang; Kunpeng Lv; Xin Liu; Xudong He; Jieti Wang; Chao Lin; Hao Liu; Heng Zhang; Hongyong He; Jiejie Xu; He Li; Ruochen Li
Journal:  Br J Cancer       Date:  2021-11-01       Impact factor: 7.640

2.  Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.

Authors:  Siyu Xia; Yun Gu; Haijian Zhang; Yuchao Fei; Yifan Cao; Hanji Fang; Jieti Wang; Chao Lin; Heng Zhang; He Li; Hongyong He; Jiejie Xu; Ruochen Li; Hao Liu; Weijuan Zhang
Journal:  Oncoimmunology       Date:  2021-09-15       Impact factor: 8.110
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.